1 originally described an inherited hematological disorder with severe neutropenia with an absolute neutrophil count (ANC) o0.2 Â 10 9
/l and an early onset of severe bacterial infections in 1956. The estimated frequency of this disorder is 1-2 cases per million with an equal distribution for gender. 2 Sepsis mortality has been reduced by treatment with granulocyte colony-stimulating factor (G-CSF), and the cumulative incidence of death from sepsis has been reported to be 8% after 10 years on G-CSF therapy. 3 In some patients who survived infections and treatment, however, the disease was reported to progress into myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment option for patients with human leukocyte antigen (HLA)-compatible donors. 4 However, there are certain risks related with this regimen regarding toxicity and treatment-related mortality for HSCT with the myeloablative conditioning regimen. In addition, myeloablative regimens that include total body irradiation may result in long-term complications such as growth retardation, problem with the endocrine functions, fertility, learning disabilities and the occurrence of second malignant neoplasms. On the other hand, reducedintensity conditioning (RIC) regimens for HSCT have been expected to be able not only to reduce the regimen related toxicity but also to prevent long-term complications. We herein report the first case to undergo an unrelated bone marrow transplantation (BMT) with fludarabine (Flu)-based RIC for the treatment of a patient with Kostmann syndrome.
The patient was the first-born child who was delivered at full term, and initially presented with cervical impetigo at 3 weeks of age. The patient's ANC was 0/ml and her bone marrow revealed a maturation arrest of neutrophil precursors at an early stage with few cells of the neutrophilic series beyond the promyelocyte stage. Based on these findings, a diagnosis of Kostmann syndrome was made. Her hematopoietic abnormality was limited to the granulocytic lineage, and her ANC never increased with neither the infections nor G-CSF. She had never had lifethreatening infections and the disease had shown neither clonal evolution nor MDS/AML.
She underwent unrelated bone marrow transplantation when she was 3 years of age, because there had been no suitable donor until then. The conditioning regimen included Flu at 25 mg/m 2 daily for 5 days (total dose 125 mg/m 2 ) and melphalan 70 mg/m 2 for 2 days (total dose 140 mg/m 2 ) in combination with anti-thymoglobulin (ATG) at 2.5 mg/kg for 2 days. Antibiotics were administered intravenously for the treatment of pneumonia until the initiation of the conditioning regimen. The donor and recipient were molecularly matched at four HLA-A and -B loci, and serologically matched at DR loci (but they were molecularly mismatched at one locus). The patient received 5.41 Â 10 8 /kg and 3.71 Â 10 6 /kg of total nucleated cells and CD34-positive cells, respectively. The prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus and short-term methotrexate. G-CSF was administered on days 7-24. Prompt engraftment was observed with an ANC of 0.5 Â 10 9 /l by day 14. The bone marrow revealed a disappearance of the maturation arrest of the myeloid series and the complete chimera of the whole blood, T-lymphocytes and granulocytes was demonstrated by the polymerase chain reaction-based amplification of a polymorphic short tandem repeat in the peripheral blood on day 119.
Acute GVHD of the skin (grade II) developed on day 15 and systemic steroid therapy was started; however, acute GVHD did not respond to systemic steroid therapy. Weekly methotrexate 10 mg/m 2 was started on day 52, and acute GVHD resolved slowly. Asymptomatic cytomegalovirus antigenemia occurred on day 40 and was treated successfully with pre-emptive ganciclovir. The patient remains well with a normal ANC count at 20 months post-transplant without any signs of chronic GVHD.
In the precytokine era, 42% of the patients with Kostmann syndrome died in their first 2 years of life, usually from sepsis and/or pneumonia. 2 Owing to the development of G-CSF therapy, now most of these patients are able to survive beyond 2 years. However, HSCT is needed in some Kostmann patients for two reasons. Some patients do not respond to G-CSF and the cumulative incidence of death from sepsis was reported 8% after 10 years on G-CSF therapy. In addition, even if they respond to G-CSF, MDS/AML is a significant risk and the cumulative incidence of MDS/AML had risen to 36% by 12 years. 3 A previous report described BMT in 11 patients without any evidence of leukemic transformation who were registered in the severe congenital neutropenia international registry between 1976 and 1998. 5 According to this report, one patient received a non-myeloablative conditioning regimen with cyclophosphamide alone; however, the patient later showed graft rejection. The other 10 patients received myeloablative regimens, and two (20%) died of complications related to acute GVHD and multiorgan failure after transplantation. Complications including hemorrhagic cystitis necessitating cystectomy, severe GVHD, extensive chronic GVHD and fungal infection have been reported. There was another case report that bilateral basal ganglial necrosis occurred in a child with Kostmann disease post-myeloablative transplant. 6 To avoid graft rejection, myeloablative regimens have thus been suggested to be better than RIC. However, the risks of regimen-related toxicity and/or treatment-related mortality remain associated with myeloablative HSCT. In addition, myeloablative regimens may result in long-term complications such as growth retardation, endocrinological disorder, infertility, learning disabilities and the occurrence of second malignant neoplasms. RIC for HSCT have been expected to be able not only to reduce the regimen-related toxicity but also to prevent long-term complications. However, to our knowledge, there are no reported data concerning to the late effects post RIC. In nonmalignant disease, the main role of the conditioning regimen is to achieve complete chimerism, as a result of immunosuppression for the host to allow for the engraftment of donor cells. We therefore administered Flu and ATG to reduce the risk of graft rejection, graft failure and GVHD. This is the first reported case that successfully underwent an unrelated BMT after conditioning with RIC for the treatment of Kostmann syndrome. The bone marrow of the recipient revealed a complete reconstitution, and a durable complete chimera was also detected. The patient remains well with normal ANC at 20 months post-transplantation. We therefore consider that patients with Kostmann syndrome who had no response to G-CSF and no evidence of MDS/AML may thus be candidates for allogeneic HSCT after conditioning with RIC. 
